TIDMIRSH
Mainstay Medical Announces Publication of Prospectus and
Admission
Mainstay Medical International plc (Mainstay or the Company,
Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical
device company focused on bringing to market ReActiv8®, an
implantable neurostimulation system to treat disabling Chronic Low
Back Pain, announces the publication of a prospectus (Prospectus)
in connection with the admission of 4,649,775 new ordinary shares
(New Shares) to trading on the regulated market of Euronext Paris.
The New Shares will also be admitted to trading on the Euronext
Growth Market of Euronext Dublin. The New Shares were issued
pursuant to a EUR13.9 million equity fundraising announced on 29
July 2019.
Application has been made to Euronext Paris and to Euronext
Dublin for the New Shares to be admitted to listing and trading on
the regulated market of Euronext Paris and to trading on the
Euronext Growth Market of Euronext Dublin, respectively
(Admission). It is expected that Admission of the New Shares will
become effective, and that dealings in the New Shares will
commence, at 8.00 a.m. Irish Standard Time / CET on 31
October2019.
The Prospectus has been approved by the Central Bank of Ireland
and is publicly available on the Company's website at
www.mainstay-medical.com/en/investors. The Company has requested
that the Central Bank of Ireland provide a certificate of approval
and a copy of the Prospectus, together with a translation of the
summary of the Prospectus into the French language, to the French
Autorité des Marchés Financiers. A translation of the summary of
the Prospectus into the French language will be shortly available
on the websites of the Company and the French Autorité des Marchés
Financiers (www.amf-france.org).
- End -
About Mainstay
Mainstay is a medical device company focused on bringing to
market an innovative implantable neurostimulation system,
ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP).
The Company is headquartered in Dublin, Ireland. It has
subsidiaries operating in Ireland, the United States, Australia,
Germany and the Netherlands, and is listed on regulated market of
the Euronext Paris (MSTY.PA) and the Euronext Growth market of
Euronext Dublin (MSTY.IE).
Further information can be found at www.mainstay-medical.com
CAUTION - in the United States, ReActiv8 is limited by federal
law to investigational use only.
PR and IR Enquiries:
LifeSci Advisors, LLCBrian RitchieTel: + 1 (212) 915-2578Email:
britchie@lifesciadvisors.com
FTI Consulting (for Ireland)Jonathan Neilan or Patrick
BerkeryTel. : +353 1 765 0886Email: mainstay@fticonsulting.com
Euronext Growth Advisers:DavyFergal Meegan or Barry MurphyTel:
+353 1 679 6363Email: fergal.meegan@davy.ie or
barry.murphy2@davy.ie
Forward looking statementsThis announcement includes statements
that are, or may be deemed to be, forward looking statements. These
forward looking statements can be identified by the use of forward
looking terminology, including the terms "anticipates", "believes",
"estimates", "expects", "intends", "may", "plans", "projects",
"should", "will", or "explore" or, in each case, their negative or
other variations or comparable terminology, or by discussions of
strategy, plans, objectives, goals, future events or intentions.
These forward looking statements include all matters that are not
historical facts. They appear throughout this announcement and
include, but are not limited to, statements regarding the Company's
intentions, beliefs or current expectations concerning, among other
things, the admission of the Company's ordinary shares to trading
on Euronext Paris and Euronext Dublin.
By their nature, forward looking statements involve risk and
uncertainty because they relate to future events and circumstances.
Forward looking statements are not guarantees of future
performance, and the actual results of the Company's operations,
the development of its main product, and the markets and the
industry in which the Company operates may differ materially from
those described in, or suggested by, the forward looking statements
contained in this announcement. In addition, even if the Company's
results of operations, financial position and growth, and the
development of its main product and the markets and the industry in
which the Company operates are consistent with the forward looking
statements contained in this announcement, those results or
developments may not be indicative of results or developments in
subsequent periods. A number of factors could cause results and
developments of the Company to differ materially from those
expressed or implied by the forward looking statements. The
forward-looking statements herein speak only at the date of this
announcement.
Disclaimers
This announcement is not an offer of securities for sale in any
jurisdiction. This announcement is not a prospectus (or prospectus
equivalent document) or an advertisement. Investors should not
subscribe for or purchase any shares in the Company based on this
announcement or the prospectus. Neither this announcement nor any
part of it shall form the basis of or be relied on in connection
with or act as an inducement to enter into any contract or
commitment whatsoever.
No reliance may be placed for any purpose on the information
contained in this announcement or its accuracy or completeness. The
material set forth herein is for information purposes only and
should not be construed as an offer of securities for sale in any
jurisdiction.
No action has been taken by the Company to permit a public offer
of New Ordinary Shares under the applicable securities laws of any
jurisdiction. Other than in Ireland and France, no action has been
taken or will be taken to permit the possession or distribution of
the Prospectus (or any other offering or publicity materials
relating to the New Ordinary Shares, including this announcement)
in any jurisdiction where action for that purpose may be required
or where doing so is restricted by law. Accordingly, neither this
announcement nor the Prospectus may be distributed or published in
any other jurisdiction except under circumstances that will result
in compliance with any applicable laws and regulations. This
announcement and the information it contains does not constitute
and shall not be considered as constituting a public offer, an
offer to subscribe or an intention to solicit the interest of the
public for a public offering of Mainstay's securities in Ireland,
France, the United Kingdom, the United States or any other
jurisdiction.
Persons into whose possession this document comes should inform
themselves about and observe any such restrictions. Any failure to
comply with these restrictions may constitute a violation of the
securities laws of any such jurisdiction.
J&E Davy ("Davy") is acting as Financial Adviser to the
Company in connection with Admission. Davy, which is regulated in
Ireland by the Central Bank of Ireland, is acting for the Company
and for no one else in connection with Admission and will not be
responsible to any person other than the Company for providing the
protections afforded to clients of Davy, nor for providing advice
in relation to Admission, the content of this announcement or any
matter referred to in this announcement. Apart from the
responsibilities and liabilities, if any, which may be imposed on
Davy by the Central Bank of Ireland, or the regulatory regime in
Ireland, neither Davy nor any of its subsidiaries, branches or
affiliates owes or accepts any duty, liability or responsibility
whatsoever (whether direct or indirect, whether in contract, in
tort, under statute or otherwise) to any person who is not a client
of Davy in connection with this announcement, any statement
contained herein or otherwise, nor makes any representation or
warranty, express or implied, in relation to, the contents of this
announcement, including its accuracy, completeness or verification
or for any other statement purported to be made by Davy, or on
behalf of Davy in connection with the Company or Admission. Davy
accordingly disclaims to the fullest extent permitted by law all
and any responsibility or liability to any person who is not a
client of Davy, whether arising in tort, contract or otherwise
(save as referred to above) which they might otherwise have in
respect of this announcement or any such statement.
This announcement does not constitute or form part of any offer
or solicitation to purchase or subscribe for, nor does it
constitute an offer to sell, or the solicitation of an offer to buy
Ordinary Shares in the United States or in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
its registration or qualification under the laws of such
jurisdiction. The New Shares mentioned herein have not been, and
will not be, registered under the U.S. Securities Act of 1933 (the
"Securities Act"). The New Shares may not be offered or sold in the
United States except pursuant to an effective registration
statement under, or an exemption from the registration requirements
of, the Securities Act. There will be no public offer of securities
in the United States.
Information to distributors
Solely for the purposes of the product governance requirements
contained within: (a) MiFID II; (b) Articles 9 and 10 of Commission
Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c)
local implementing measures (together, the "MiFID II Product
Governance Requirements"), and disclaiming all and any liability,
whether arising in tort, contract or otherwise, which any
"manufacturer" (for the purposes of the MiFID II Product Governance
Requirements) may otherwise have with respect thereto, the New
Shares have been subject to a product approval process, which has
determined that such New Shares are: (i) compatible with an end
target market of retail investors and investors who meet the
criteria of professional clients and eligible counterparties, each
as defined in MiFID II; and (ii) eligible for distribution through
all distribution channels as are permitted by MiFID II (the "Target
Market Assessment"). Notwithstanding the Target Market Assessment,
distributors should note that: the price of the New Shares may
decline and investors could lose all or part of their investment;
the New Shares offer no guaranteed income and no capital
protection; and an investment in the New Shares is compatible only
with investors who do not need a guaranteed income or capital
protection, who (either alone or in conjunction with an appropriate
financial or other adviser) are capable of evaluating the merits
and risks of such an investment and who have sufficient resources
to be able to bear any losses that may result therefrom. The Target
Market Assessment is without prejudice to the requirements of any
contractual, legal or regulatory selling restrictions in relation
to the offer of the New Shares. For the avoidance of doubt, the
Target Market Assessment does not constitute: (a) an assessment of
suitability or appropriateness for the purposes of MiFID II; or (b)
a recommendation to any investor or group of investors to invest
in, or purchase, or take any other action whatsoever with respect
to the New Shares. Each distributor is responsible for undertaking
its own target market assessment in respect of the New Shares and
determining appropriate distribution channels.
This distribution of this announcement may be subject to legal
or regulatory restrictions in certain jurisdictions. Any person who
comes into possession of this announcement must inform him or
herself of and comply with any such restrictions.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20191025005315/en/
This information is provided by Business Wire
(END) Dow Jones Newswires
October 25, 2019 11:00 ET (15:00 GMT)
Mainstay Medical (LSE:0QUD)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Mainstay Medical (LSE:0QUD)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024